<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628221</url>
  </required_header>
  <id_info>
    <org_study_id>OP2020</org_study_id>
    <nct_id>NCT04628221</nct_id>
  </id_info>
  <brief_title>Open Label Study Using OsteoProbe System</brief_title>
  <acronym>OP</acronym>
  <official_title>A Single-Arm, Open Label Clinical Study to Collect Safety Data on the Osteoprobe System When Used as a Measurement Tool</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Active Life Scientific, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCRA, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Active Life Scientific, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Single Center, Open Label Clinical Study. The purpose of the study is to collect&#xD;
      safety data associated with the use of the OsteoProbe System. Study Duration is expected to&#xD;
      take approximately 3 months from first subject enrolled to the last follow-up visit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With Reported Device Related Serious Adverse Events.</measure>
    <time_frame>Procedure</time_frame>
    <description>The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants With Reported Device Related Serious Adverse Events.</measure>
    <time_frame>1-day follow up visit</time_frame>
    <description>The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants With Reported Device Related Serious Adverse Events.</measure>
    <time_frame>7-day follow up visit</time_frame>
    <description>The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants With Reported Device Related Serious Adverse Events.</measure>
    <time_frame>30-day follow up visit</time_frame>
    <description>The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Scores</measure>
    <time_frame>Post-procedure, 1-day, 7-day and 30-day follow up visits</time_frame>
    <description>The Numeric Rating Scale (NRS) is a continuous scale comprised of a line, with an eleven point numeric range (0 to 10) anchored by 2 verbal descriptors, one for each symptom extreme. The 0 mark corresponds to 'no pain', while the 10 mark corresponds to 'worse pain possible'. Therefore, higher scores indicate greater pain intensity. At all follow-up time points (post-procedure, Day 1, Day 7 , and Day 30), average was taken compared to baseline (Pre-Procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMSi Scores</measure>
    <time_frame>Procedure</time_frame>
    <description>BSMi Score is an output measure by the OsteoProbe device to measure bone tissue's resistance to microindentation which can be positively correlated with bone tissue quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Procedure through day 30</time_frame>
    <description>The number of participants who experienced an adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Device-related Adverse Events</measure>
    <time_frame>Procedure through day 30</time_frame>
    <description>The number of participants who experienced an device-related adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Procedure through day 30</time_frame>
    <description>The number of participants who experienced a Serious adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated Adverse Device Effects (UADE)</measure>
    <time_frame>Procedure through day 30</time_frame>
    <description>The number of participants who experienced a Unanticipated adverse device effects.</description>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Adverse Effects in the Use of the OsteoProbe System</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OsteoProbe System</intervention_name>
    <description>The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be greater than or equal to 22 years of age;&#xD;
&#xD;
          2. Be able to give voluntary, written informed consent to participate and have signed an&#xD;
             Informed Consent Form specific to this study&#xD;
&#xD;
          3. If female and of child-bearing potential, must have a negative pregnancy status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active skin infection at the procedure site as identified during a SOC physical&#xD;
             examination.&#xD;
&#xD;
          2. Subject-reported or known systemic infection;&#xD;
&#xD;
          3. Subject-reported or known allergy to local anesthetic;&#xD;
&#xD;
          4. Subject-reported or known allergy to stainless steel or nickel materials;&#xD;
&#xD;
          5. Subject-reported or known current use of systemic antibiotics, or topical antibiotics&#xD;
             administered to the procedure site;&#xD;
&#xD;
          6. Subject-reported or known history of needle phobia;&#xD;
&#xD;
          7. Significant soft tissue at the procedure site which would preclude use of the&#xD;
             OsteoProbe in the judgement of the Investigator;&#xD;
&#xD;
          8. Known instance of hardware in the tibia that is intended to be measured based on&#xD;
             radiographic imaging;&#xD;
&#xD;
          9. Known instance of a previous or current fracture in the tibia that is intended to be&#xD;
             measured based on radiographic imaging;&#xD;
&#xD;
         10. Are known to be actively participating or known to have participated in another&#xD;
             clinical investigation for which they received an investigational product (including&#xD;
             but not limited to a drug or vaccine) within the last 90 days, or reports that they&#xD;
             intend to participate in another clinical investigation during the course of the&#xD;
             study;&#xD;
&#xD;
         11. Are known to be currently abusing drugs or alcohol or have a known history of the same&#xD;
             within the last 12 months;&#xD;
&#xD;
         12. Have any known or subject reported mental or psychological disorders that, in the&#xD;
             judgement of the Investigator, would impair their ability to accurately complete the&#xD;
             NRS Pain Score surveys;&#xD;
&#xD;
         13. Are currently a prisoner;&#xD;
&#xD;
         14. Have a condition which, in the judgement of the Investigator, would preclude adequate&#xD;
             evaluation of the device's safety and performance. Conditions include but are not&#xD;
             limited to:&#xD;
&#xD;
               1. Regional or systemic pain syndromes&#xD;
&#xD;
               2. Radicular pain syndromes&#xD;
&#xD;
               3. Chronic or intermittent leg pain&#xD;
&#xD;
               4. Migraine headaches&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <results_first_submitted>February 26, 2021</results_first_submitted>
  <results_first_submitted_qc>March 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2021</results_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04628221/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OsteoProbe System</title>
          <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OsteoProbe System</title>
          <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.95" spread="14.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
        <description>The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.</description>
        <time_frame>Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
          <description>The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
        <description>The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.</description>
        <time_frame>1-day follow up visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
          <description>The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
        <description>The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.</description>
        <time_frame>7-day follow up visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
          <description>The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
        <description>The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.</description>
        <time_frame>30-day follow up visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Reported Device Related Serious Adverse Events.</title>
          <description>The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Scores</title>
        <description>The Numeric Rating Scale (NRS) is a continuous scale comprised of a line, with an eleven point numeric range (0 to 10) anchored by 2 verbal descriptors, one for each symptom extreme. The 0 mark corresponds to 'no pain', while the 10 mark corresponds to 'worse pain possible'. Therefore, higher scores indicate greater pain intensity. At all follow-up time points (post-procedure, Day 1, Day 7 , and Day 30), average was taken compared to baseline (Pre-Procedure).</description>
        <time_frame>Post-procedure, 1-day, 7-day and 30-day follow up visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Scores</title>
          <description>The Numeric Rating Scale (NRS) is a continuous scale comprised of a line, with an eleven point numeric range (0 to 10) anchored by 2 verbal descriptors, one for each symptom extreme. The 0 mark corresponds to 'no pain', while the 10 mark corresponds to 'worse pain possible'. Therefore, higher scores indicate greater pain intensity. At all follow-up time points (post-procedure, Day 1, Day 7 , and Day 30), average was taken compared to baseline (Pre-Procedure).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMSi Scores</title>
        <description>BSMi Score is an output measure by the OsteoProbe device to measure bone tissue's resistance to microindentation which can be positively correlated with bone tissue quality.</description>
        <time_frame>Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>BMSi Scores</title>
          <description>BSMi Score is an output measure by the OsteoProbe device to measure bone tissue's resistance to microindentation which can be positively correlated with bone tissue quality.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.35" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>The number of participants who experienced an adverse event.</description>
        <time_frame>Procedure through day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>The number of participants who experienced an adverse event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Device-related Adverse Events</title>
        <description>The number of participants who experienced an device-related adverse event.</description>
        <time_frame>Procedure through day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Device-related Adverse Events</title>
          <description>The number of participants who experienced an device-related adverse event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>The number of participants who experienced a Serious adverse event.</description>
        <time_frame>Procedure through day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>The number of participants who experienced a Serious adverse event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unanticipated Adverse Device Effects (UADE)</title>
        <description>The number of participants who experienced a Unanticipated adverse device effects.</description>
        <time_frame>Procedure through day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OsteoProbe System</title>
            <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
          </group>
        </group_list>
        <measure>
          <title>Unanticipated Adverse Device Effects (UADE)</title>
          <description>The number of participants who experienced a Unanticipated adverse device effects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OsteoProbe System</title>
          <description>OsteoProbe System: The OsteoProbeÂ® System (&quot;OsteoProbe&quot;) is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nicole Harris</name_or_title>
      <organization>MCRA, LLC</organization>
      <phone>202-552-5800 ext 5823</phone>
      <email>nharris@mcra.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

